Dr. Baldino, founder of the Company, has served as Chief Executive Officer and
director since the Company's inception. He was appointed Chairman of the Board
of Directors in 1999. He currently serves as a director of Acusphere, Inc., a
drug delivery company, NicOx S.A., a company engaged in the research, development
and commercialization of nitric oxide therapeutics, and Viropharma, Inc., a developer
of proprietary antiviral pharmaceuticals for treatment of viral diseases. Dr.
Baldino also holds several adjunct academic appointments and is a trustee of Temple
University.
Mr. Aragues was appointed as Executive Vice President and President of Cephalon
Europe in January 2010. Mr. Aragues joined Cephalon in 2002 to lead the company's
expansion in France following its 2001 acquisition of Group Lafon and was appointed
President of Cephalon Europe in February 2005. Prior to joining Cephalon, Mr.
Aragues held various senior positions in the pharmaceutical industry at DuPont
Pharmaceuticals in Europe and in the United States as well as at Bristol-Myers
Squibb Pharma France. In February 2008, Mr. Aragues was awarded the highest
French Distinction as Chevalier de la Légion d'Honneur by the French
Minister of Health, Mrs. Roselyne Bachelot. Mr. Aragues graduated from Institut
des Sciences Politiques of Toulouse in France with a Master in Economy, Finance
and Business Administration.
Ms. Baldassano joined Cephalon in October 2007 as Executive Vice President
and Chief Compliance Officer. From April to September 2007, Ms. Baldassano served
as Partner with Fox Rothschild LLP in Philadelphia where she was a member of
the litigation department and the founding member of the White Collar Compliance
and Defense Practice Group. Between January 2004 and March 2007, Ms. Baldassano
served as Vice President Global Compliance for Schering-Plough. Between 1999
and 2003, Ms. Baldassano service as Senior Director, Global Compliance and Associate
General Counsel for Pharmacia. Between 1990 and 1998, Ms. Baldassano was with
the U.S. Attorney's Office in the Eastern District of Pennsylvania. Ms. Baldassano
graduated from Georgetown University and received her J.D. from Syracuse University.
Mr. Buchi joined Cephalon in March 1991 and, since January 2010, he has served
as Chief Operating Officer. From February 2006 through January 2010, Mr. Buchi
was Executive Vice President and Chief Financial Officer. From April 1996 through
January 2006, he served as Senior Vice President and Chief Financial Officer,
and he held several financial positions with the Company prior to April 1996.
Between 1985 and 1991, Mr. Buchi served in a number of financial positions with
E.I. du Pont de Nemours and Company. Mr. Buchi received a master of management
degree from the J.L. Kellogg Graduate School of Management, Northwestern University
in 1982 and is a certified public accountant. Mr. Buchi serves as a member of
the board of directors of Celator Pharmaceuticals, Inc., a privately-held pharmaceutical
company.
Dr. Grebow joined Cephalon in January 1991 and, since February 2005, he has
served as Executive Vice President, Worldwide Technical Operations. Dr. Grebow
also has served as Senior Vice President, Worldwide Technical Operations, Senior
Vice President, Business Development, and Vice President, Drug Development.
From 1988 to 1990, Dr. Grebow served as Vice President of Drug Development for
Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc.,
a pharmaceutical company. Dr. Grebow serves as a member of the board of directors
of Optimer Pharmaceuticals, Inc., a publicly-traded biotechnology company. Dr.
Grebow received a Ph.D. in chemistry from the University of California, Santa
Barbara.
Mr. Groenhuysen joined Cephalon in August 2007 as Senior Vice President of
Finance. Since January 2010, he has held the position of Executive Vice President
& CFO with responsibility for Worldwide Finance, Commercial Operations and
Risk Management. Prior to joining Cephalon he spent 20 years with Philips Electronics
in various assignments in Europe, Asia and the United States, the latest of
which started in 2002 when he was promoted to Senior Vice President and Chief
Financial Officer of Philips Electronics North America Corporation.
Mr. Pappert joined Cephalon in May 2008 as Executive Vice President and General
Counsel. In October 2008, Mr. Pappert assumed the responsibilities of the Company
Secretary. Prior to coming to Cephalon, Mr. Pappert was a partner with Ballard
Spahr Andrews & Ingersoll LLP in Philadelphia, PA, where he was a member
of the Litigation Department. From 2003 to 2005, Mr. Pappert was the Commonwealth
of Pennsylvania Attorney General. From 1997 to 2003, he held the position of
First Deputy Attorney General of Pennsylvania. Mr. Pappert is a graduate of
Villanova University and earned his Juris Doctorate from the University of Notre
Dame Law School.
Dr. Russell joined Cephalon in January 2000 and, since August 2008, she has
served as Executive Vice President and Chief Medical Officer. From November
2006 to August 2008, Dr. Russell served as Executive Vice President, Worldwide
Medical and Regulatory Operations. From January 2000 to August 2006, Dr. Russell
was Senior Vice President of Worldwide Clinical Research with the Company. Dr.
Russell came to Cephalon in January 2000 from US Bioscience Inc./Medimmune Oncology,
where she was Vice President Clinical Research, responsible for directing and
implementing the clinical programs in oncology and HIV research. Prior to joining
US Bioscience, Dr. Russell was Director of Clinical Research at USB Pharma Ltd,
the European subsidiary of US Bioscience. Before her work at USB Pharma, Dr.
Russell was a Clinical Research Physician at Eli Lilly UK, responsible for the
oncology clinical trial program in the UK. Dr. Russell was Medical Director
at Amgen UK from May 1992 to May 1995. Before joining the pharmaceutical industry,
Dr. Russell was trained in Hematology/Oncology at Royal Infirmary of Edinburgh,
and Royal Hospital for Sick Children Edinburgh UK and was a Research Fellow
at University of Edinburgh Faculty of Medicine. Dr. Russell serves as a member
of the board of directors of AMAG Pharmaceuticals, Inc., a biopharmaceutical
company. Dr. Russell received MB.Ch.B. from University of Edinburgh, Scotland,
Faculty of Medicine and is a member of the Royal College of Physicians, UK.
Mr. Savini joined Cephalon in June 1993 and, since February 2006, he has served
as Executive Vice President and Chief Administrative Officer. Mr. Savini has
served in various capacities with the Company, including Senior Vice President,
Administration and Senior Vice President, Human Resources. From 1983 to 1993,
Mr. Savini was employed by Bristol-Myers Squibb Company and from 1981 to 1983
he was employed by Johnson & Johnson's McNeil Pharmaceuticals. Mr. Savini
graduated from The Pennsylvania State University and received a master of business
administration degree from La Salle College.
Dr. Vaught joined Cephalon in August 1991 and, since August 2008, he has served
as Executive Vice President and Chief Scientific Officer responsible for directing
Cephalon's research operations. Prior to joining Cephalon, Dr. Vaught was employed
by the R. W. Johnson Pharmaceutical Research Institute, a subsidiary of Johnson
& Johnson. Dr. Vaught received a Ph.D. in pharmacology from the University
of Minnesota.
